Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients

Nenhuma Miniatura disponível
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
DAHARI, H.
NEUMANN, A. U.
LAYDEN, T. J.
COTLER, S. J.
Citação
JOURNAL OF VIRAL HEPATITIS, v.18, n.4, p.e52-e60, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The objective of this study was to find very early viral kinetic markers to predict nonresponse to hepatitis C virus (HCV) therapy in a group of human immunodeficiency virus (HIV)/HCV-coinfected patients. Twenty-six patients (15 HCV genotype-1 and 11 genotype-3) were treated with a 48-week regimen of peginterferon-alfa-2a (PEG-IFN) (180 mu g/week) and weight-based ribavirin (11 mg/kg/day). Samples were collected at baseline; 4, 8, 12, 18, 24, 30, 36 and 42 h; days 2, 3, 4, 7, 8, 15, 22, 29, 43 and 57 then weekly and monthly. Five patients discontinued treatment. Seven patients (27%) achieved a sustained virological response (SVR). Nadir HCV RNA levels were observed 1.6 +/- 0.3 days after initiation of therapy, followed by a 0.3- to 12.9-fold viral rebound until the administration of the second dose of PEG-IFN, which were not associated with SVR or HCV genotype. A viral decline < 1.19 log for genotype-1 and < 0.97 log for genotype-3, 2 days after starting therapy, had a negative predictive value (NPV) of 100% for SVR. The day 2 virological response had a similar positive predictive value for SVR as a rapid virological response at week 4. In addition, a second-phase viral decline slope (i.e., measured from day 2 to 29) < 0.3 log/week had a NPV = 100% for SVR. We conclude that first-phase viral decline at day 2 and second-phase viral decline slope (< 0.3 log/week) are excellent predictors of nonresponse. Further studies are needed to validate these viral kinetic parameters as early on-treatment prognosticators of nonresponse in patients with HCV and HIV.
Palavras-chave
HCV, HIV, pegylated interferon, viral kinetics
URI
https://observatorio.fm.usp.br/handle/OPI/23065
Referências
  1. Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103
  2. Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
  3. Durante-Mangoni E, 2009, CLIN INFECT DIS, V49, P498, DOI 10.1086/600887
  4. Martin-Carbonero L, 2008, AIDS, V22, P15
  5. Carrat F, 2004, JAMA-J AM MED ASSOC, V292, P2839, DOI 10.1001/jama.292.23.2839
  6. Chung RT, 2004, NEW ENGL J MED, V351, P451, DOI 10.1056/NEJMoa032653
  7. Torriani FJ, 2004, NEW ENGL J MED, V351, P438, DOI 10.1056/NEJMoa040842
  8. Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
  9. Alberti A, 2005, J HEPATOL, V42, P615, DOI 10.1016/j.jhep.2005.03.003
  10. Chen TY, 2009, CLIN INFECT DIS, V49, P1605, DOI 10.1086/644771
  11. Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
  12. Zeuzem S, 2008, ANTIVIR THER, V13, P747
  13. Cotler SJ, 2003, J VIRAL HEPATITIS, V10, P43, DOI 10.1046/j.1365-2893.2003.00401.x
  14. Herrmann E, 2003, HEPATOLOGY, V37, P1351, DOI 10.1053/jhep.2003.50218
  15. Layden-Almer JE, 2003, HEPATOLOGY, V37, P1343, DOI 10.1053/jhep.2003.50217
  16. Pawlotsky JM, 2004, GASTROENTEROLOGY, V126, P703, DOI 10.1053/j.gastro.2003.12.002
  17. Nunez M, 2007, JAIDS-J ACQ IMM DEF, V45, P439
  18. Layden JE, 2002, J VIRAL HEPATITIS, V9, P340, DOI 10.1046/j.1365-2893.2002.00377.x
  19. Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501
  20. Dahari H, 2010, J HEPATOL, V53, P460, DOI 10.1016/j.jhep.2010.03.019
  21. Arends JE, 2005, NETH J MED, V63, P156
  22. Avidan NU, 2009, JAIDS-J ACQ IMM DEF, V52, P452, DOI 10.1097/QAI.0b013e3181be7249
  23. Ballesteros AL, 2004, AIDS, V18, P59, DOI 10.1097/01.aids.0000104370.21567.a3
  24. Boehme RE, 2009, ANTIVIR THER, V14, P1195, DOI 10.3851/IMP1470
  25. Dahari H, 2007, J HEPATOL, V47, P23, DOI 10.1016/j.jhep.2007.01.027
  26. Dahari H., 2008, Current Hepatitis Reports, V7, P97, DOI 10.1007/s11901-008-0022-2
  27. Ferenci P, 2004, J ANTIMICROB CHEMOTH, V53, P15, DOI 10.1093/jac/dkh015
  28. FERREIRA P, 2010, COINFECCCAO VHC HIV, P280
  29. Howell CD, 2010, J HEPATOL, V52, pS451
  30. Howell CD, 2008, CLIN GASTROENTEROL H, V6, P575, DOI 10.1016/j.cgh.2008.02.035
  31. Laguno M, 2007, JAIDS-J ACQ IMM DEF, V44, P174, DOI 10.1097/QAI.0b013e31802b812d
  32. Medeiros-Filho JE, 2006, WORLD J GASTROENTERO, V12, P7271
  33. NIH, 2002, HEPATOLOGY, V36, pS3
  34. Perelson AS, 2005, HEPATOLOGY, V42, P749, DOI 10.1002/hep.20882
  35. Rockstroh JK, 2006, CURR OPIN INFECT DIS, V19, P8, DOI 10.1097/01.qco.0000200294.22661.e0
  36. Rozenberg L, 2009, AIDS, V23, P2439, DOI 10.1097/QAD.0b013e32832ff1c0
  37. Soriano V, 2004, AIDS, V18, P1, DOI 10.1097/01.aids.0000096896.73209.52
  38. Soriano V, 2005, CURR OPIN INFECT DIS, V18, P550, DOI 10.1097/01.qco.0000191509.56104.ec
  39. Sulkowski MS, 2000, CLIN INFECT DIS, V30, pS77, DOI 10.1086/313842
  40. Talal AH, 2006, HEPATOLOGY, V43, P943, DOI 10.1002/hep.21136
  41. Thomas DL, 2006, J HEPATOL, V44, pS40, DOI 10.1016/j.jhep.2005.11.011
  42. Burgess J, 2005, AM J GASTROENTEROL, V100, P2338, DOI 10.1111/j.1572-0241.2005.00222.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/47